BridgeBio Pharma Inc. (BBIO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
BridgeBio Pharma Inc. (BBIO) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (54/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (-14.4% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How BBIO Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $502.1M | 95.8% | -104.2% | $0 | -$447.0M | -45% |
| FY 2024 | $221.9M | 98.3% | -267.2% | $0 | -$521.7M | -45% |
| FY 2023 | $9.3M | 44% | -6528.8% | $0 | -$528.1M | -10.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BBIO)
- ✓Live walkthrough of BBIO's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
BBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +126.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BBIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BBIO. Explore sector supply chains on /butterfly.
BBIO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is BridgeBio Pharma Inc. (BBIO)?
In FY 2025 (10-K), BBIO converted $502.1M of revenue into a 95.8% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).